Nestlé: advances gastrointestinal program with Codexis
(CercleFinance.com) - Nestlé and US protein engineering company Codexis will advance a new enzyme therapy candidate to treat digestive disorders into preclinical development and early clinical studies, the companies said on Friday.
The two partners said that they have agreed to advance the development of CDX-7108, the lead candidate for a potential treatment of a gastrointestinal disorder.
In 2017 Nestlé and Codexis signed a strategic collaboration agreement to co-discover new enzyme therapy candidates for Nestlé Health Science's nutritional portfolio.
The deal will be extended through the end of 2021 to support the discovery of therapeutic candidates for additional disorders, the companies said Friday.
Copyright (c) 2020 CercleFinance.com. All rights reserved.
The two partners said that they have agreed to advance the development of CDX-7108, the lead candidate for a potential treatment of a gastrointestinal disorder.
In 2017 Nestlé and Codexis signed a strategic collaboration agreement to co-discover new enzyme therapy candidates for Nestlé Health Science's nutritional portfolio.
The deal will be extended through the end of 2021 to support the discovery of therapeutic candidates for additional disorders, the companies said Friday.
Copyright (c) 2020 CercleFinance.com. All rights reserved.